Baxter International Inc. (NYSE:BAX), a global leader in injectables, anesthesia and drug compounding, today announced five ...

SAN DIEGO -- A fixed-duration oral combination significantly reduced the risk of disease progression or death compared with ...

-Company expects to provide a broader update across oncology and autoimmune indications in mid-2025- ...

Patients treated with Polivy in combination with R-CHP required fewer subsequent treatments, potentially reducing burdens on patients and healthcare systems1 These encouraging five-year results ...

Studies include the Phase III SUNMO trial evaluating the efficacy and safety of subcutaneously administered Lunsumio ® (mosunetuzumab-axgb) in combination with intravenous (IV) Polivy versus IV ...